OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Breast Cancer · Advanced Breast Cancer · Metastatic Breast Cancer · ER Positive Breast Cancer · HER2 Negative Breast Carcinoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 510 (planned)
- Started
- Nov 16, 2023
- Main results expected
- Oct 31, 2026
- Fully finished
- Feb 29, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Dose-Selection Part: Incidence of adverse events
Measured over: From Date of Randomization up to 16 weeks
Dose-Selection Part: Incidence of dose reduction
Measured over: From Date of Randomization up to 16 weeks
Dose-Selection Part: Incidence of drug discontinuation
Measured over: From Date of Randomization up to 16 weeks
Trial: Progression-Free Survival (PFS)
Measured over: From Date of Randomization until Disease Progression or Death Due to Any Cause (estimated as up to 2 years)
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06016738 · record last updated 2026-08-13 · checked 2026-11-09 15:47 UTC